CompanyENTANasdaqWatertown, MA

Enanta Pharmaceuticals Inc

Enanta discovers and develops small molecule drugs for viral infections and immunological diseases.

SEC EDGAR ClinicalTrials.gov enanta.com

SCHEDULE 13G/AAug 14Latest SEC filing

Aug 19Latest story

August 2026

Enanta posts results for Phase 2b EDP-938 RSV trial in high-risk adults

Aug 19Trial updateEDP-938 Enanta Pharmaceuticals Inc

Enanta reports fiscal Q3 2026 results, dosing underway in pediatric RSV trial

Aug 10Quarterly updateEnanta Pharmaceuticals Inc zelicapavir

July 2026

Enanta details $75 million at-the-market stock program with Jefferies, cites $9.23 dilution

Jul 2FinancingEnanta Pharmaceuticals Inc

Enanta sets up $75 million at-the-market stock sale program with Jefferies

Jul 2PartnershipEnanta Pharmaceuticals Inc